Compound Summary
piracetam
Compound Information
piracetam
Compound Name: | piracetam |
Compound CID: | 4843 |
Synonyms: | piracetam 7491-74-9 2-(2-oxopyrrolidin-1-yl)acetamide Nootropil 2-Oxo-1-pyrrolidineacetamide More... |
Iupac Name: | 2-(2-oxopyrrolidin-1-yl)acetamide |
InChI: | InChI=1S/C6H10N2O2/c7-5(9)4-8-3-1-2-6(8)10/h1-4H2,(H2,7,9) |
InChIKey: | GMZVRMREEHBGGF-UHFFFAOYSA-N |
Canonical Smiles: | C1CC(=O)N(C1)CC(=O)N |
Isomeric Smiles: | C1CC(=O)N(C1)CC(=O)N |
Molecular Weight: | 142.16 |
Molecular Formula: | C6H10N2O2 |
Compound Structure
2D Structure:
3D Structure:
Computed Properties
piracetam
Molecular Weight: | 142.16 |
Molecular Formula: | C6H10N2O2 |
Hydrogen Bond Donor Count: | 1 |
Hydrogen Bond Acceptor Count: | 2 |
Rotatable Bond Count: | 2 |
Heavy Atom Count: | 10 |
Complexity: | 167 |
Synonyms
piracetam
| piracetam | piracetam |
|---|---|
piracetam |
7491-74-9 |
2-(2-oxopyrrolidin-1-yl)acetamide |
Nootropil |
2-Oxo-1-pyrrolidineacetamide |
Nootropyl |
Pyracetam |
1-Pyrrolidineacetamide, 2-oxo- |
Normabrain |
Gabacet |
Pyramem |
Genogris |
Pirroxil |
Euvifor |
Nootron |
2-Pyrrolidinoneacetamide |
2-Oxo-pyrrolidine acetamide |
2-Pyrrolidoneacetamide |
UCB 6215 |
UCB-6215 |
2-(2-oxo-pyrrolidin-1-yl)acetamide |
2-Oxo-pyrrolidin-1-ylacetamide |
2-Ketopyrrolidine-1-ylacetamide |
Cl-871 |
UNII-ZH516LNZ10 |
2-(2-Oxopyrrolidino)acetamide |
MLS000069719 |
2-(2-Oxo-1-pyrrolidinyl)acetamide |
SMR000058196 |
ZH516LNZ10 |
Ciclofalina |
Pirazetam |
NCGC00015821-02 |
CAS-7491-74-9 |
DSSTox_CID_24491 |
DSSTox_RID_80267 |
DSSTox_GSID_44491 |
2-(2-oxopyrrolidinyl)acetamide |
Naofukang Chinese |
Cerebroforte |
Piracetamum |
Avigilen |
Breinox |
Naofukang |
Nootrop |
Norzetam |
Axonyl |
Geram |
Piracetamum INN-Latin |
KT-801 |
Deshydroxy Oxiracetam |
SR-01000076071 |
EINECS 231-312-7 |
BRN 1526393 |
Encetrop |
Piracetam USAN:INN:BAN |
HSDB 7529 |
Piracetam,(S) |
Prestwick_870 |
Myocalm (TN) |
Spectrum_001421 |
Opera_ID_1766 |
Prestwick0_000537 |
Prestwick1_000537 |
Prestwick2_000537 |
Prestwick3_000537 |
Spectrum2_001074 |
Spectrum3_001523 |
Spectrum4_000742 |
Spectrum5_001037 |
Lopac-P-5295 |
cid_4843 |
Lopac0_000949 |
Oprea1_512927 |
SCHEMBL20172 |
BSPBio_000553 |
BSPBio_002906 |
KBioGR_001064 |
KBioSS_001901 |
5-21-06-00360 (Beilstein Handbook Reference) |
Piracetam (JAN/USAN/INN) |
CHEMBL36715 |
DivK1c_000259 |
SPECTRUM1502195 |
SPBio_001088 |
SPBio_002474 |
2-(2-ketopyrrolidino)acetamide |
BPBio1_000609 |
GTPL4288 |
DTXSID5044491 |
BDBM62877 |
CHEBI:32010 |
Cl-781 |
HMS500M21 |
KBio1_000259 |
KBio2_001901 |
KBio2_004469 |
KBio2_007037 |
KBio3_002406 |
NINDS_000259 |
HMS1569L15 |
HMS1921L12 |
HMS2092D18 |
HMS2096L15 |
HMS2230B24 |
HMS3262N20 |
HMS3371G01 |
HMS3657A05 |
HMS3713L15 |
HMS3885I07 |
Pharmakon1600-01502195 |
BCP28414 |
HY-B0585 |
ZINC3812874 |
Tox21_110229 |
Tox21_301990 |
Tox21_500949 |
BBL028161 |
CCG-39282 |
MFCD00079246 |
NSC758191 |
s3070 |
SBB086233 |
STK535612 |
2 - Oxo - 1 - pyrrolidineacetamide |
AKOS001038683 |
Tox21_110229_1 |
2-(2-Oxo-1-pyrrolidinyl)acetamide # |
DB09210 |
LP00949 |
MCULE-7645397226 |
NSC 758191 |
NSC-758191 |
SDCCGSBI-0050923.P004 |
IDI1_000259 |
NCGC00015821-01 |
NCGC00015821-03 |
NCGC00015821-04 |
NCGC00015821-05 |
NCGC00015821-06 |
NCGC00015821-07 |
NCGC00015821-08 |
NCGC00015821-10 |
NCGC00015821-21 |
NCGC00094253-01 |
NCGC00094253-02 |
NCGC00094253-03 |
NCGC00094253-04 |
NCGC00255727-01 |
NCGC00261634-01 |
AC-33158 |
AS-13920 |
BP166248 |
K282 |
SBI-0050923.P003 |
AB0014139 |
DB-019407 |
AB00052287 |
EU-0100949 |
FT-0636504 |
ST50182453 |
SW196995-3 |
2-(2-oxidanylidenepyrrolidin-1-yl)ethanamide |
Piracetam, VETRANAL(TM), analytical standard |
D01914 |
P 5295 |
96625-EP2287163A1 |
96625-EP2305678A1 |
AB00052287_12 |
A838261 |
AE-641/30117005 |
Q410069 |
SR-01000076071-1 |
SR-01000076071-4 |
SR-01000076071-6 |
W-104408 |
BRD-K19456237-001-22-7 |
Z56865289 |
Piracetam, European Pharmacopoeia (EP) Reference Standard |
Experimental Data
piracetam
| Species | Dose | Unit | Control(Avg days) | Treatment(Avg days) | Avg/Med Lifespan Change(%) | Control(Max days) | Treatment(Max days) | Max Lifespan Change(%) | Significant | Strain | Gender | PubMed | Avg/Med Lifespan Change tab |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Caenorhabditis elegans | 33.000000000000000 | umol/L | 6.000000000000000 | NS | N2 | 24134630 | Inactive |
Experimental Data Visualization
piracetam
Statistics Data
piracetam
| Species | Avg/Med Lifespan Change(%) | Max Lifespan Change(%) | Count Reference | Count Data point |
|---|---|---|---|---|
| Caenorhabditis elegans | 6.000000000000000 | 1 | 1 |
Statistics Data Visualization
piracetam
